Previous 10 | Next 10 |
Major benchmarks generally did well on Friday, as investors were pleased to get good news on the employment front to help counter some of the weaker readings in economic data in recent days. After such a significant pullback in stocks, many market participants also seemed ready to have at least ...
The following slide deck was published by Heron Therapeutics, Inc. in conjunction with this Read more ...
Arbutus Biopharma (NASDAQ: ABUS ) -25% after a decision to stop development of AB-506. More news on: Arbutus Biopharma Corporation, Ovid Therapeutics Inc., PDS Biotechnology Corporation, Stocks on the move, Read more ...
Heron Therapeutics (NASDAQ: HRTX ) prices its public offering of 8.57M common shares at $17.50/share, for gross proceeds of ~$150M. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Read more ...
SAN DIEGO , Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...
A lion doesn't concern itself with the opinion of sheep .”― George R.R. Martin, A Game of Thrones It has been a trying ten days or so for biotech investors. The SPDR Biotech ETF ( XBI ) was down over seven percent last week and is down again this week. Some biotech compani...
Heron Therapeutics (NASDAQ: HRTX ) is 4.5% lower after hours following its announcement of a proposed public offering of common stock . More news on: Heron Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SAN DIEGO , Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...
SAN DIEGO , Oct. 2, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced positive ...
SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechn...